Denali Therapeutics (DNLI +1.5%) announces that collaboration partner Sanofi (SNY -0.7%) has started dosing in a Phase 1b clinical trial evaluating DNL758 (dubbed SAR443122 by Sanofi) in hospitalized patients with severe COVID-19 lung disease.
Small molecule DNL758 inhibits an enzyme called receptor-interacting serine/threonine-protein kinase 1 (RIPK1) that plays a key role in inflammation and cell death.
The companies’ partnership, inked in October 2018, is aimed at developing, manufacturing and commercializing RIPK1 inhibitors in neurological and systemic inflammatory diseases.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.